References
- Biopharm. Drug Dispos. v.12 Bioavailabiltity of diltiazem as a function of the administered dose Bianchetti,G.;Regazzi,M.;Rondanelli,R.;Ascalone,V.;Morselli,P.L.
- J. Cardiovasc. Pharmacol. v.6 Clinical pharmacology of calcium antagonists Eichelbaum,M.;Echizen,H.I.
- Am. J. Kidney Dis. v.16 Effects of calcium antagonists on renal hemodynamics Epstein,M.;Loutzenhiser,R.D.
- Am. J. Kidney Dis. v.345 High performance liquid chromatographic dertermination of diltiazem and four of its metabolites in plasma Goebel,K.J.;Kolle,E.U.
- J. Clin. Pharmacol. v.28 Pharmacokinetics of diltiazem in patients undergoing continuous ambulatory peritoneal dialysis Grech-Belanger,O.;Langlois,S.;LeBoeuf,E.
- Eur. J. Clin. Pharmacol. v.24 Pharmcokinetics of diltiazem after intravenous and oral administration Hermann,P.;Rodger,S.D.;Remones,G.;Thenot,J.P.;London,D.R.
- Pharm. Res. v.12 Metabolism of diltiazem in hepatic and extrahepatic tissues of rabbits Homsy,W.;Lefebvre,M.;Caille,G.;du Souich P.I.
- Drug Metab. Dispos. v.15 Deacetylation of diltiazem by rat liver Leboeuf,F.;Grech Belanger,O.I.
- Pharm. Res. v.12 Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrate-induced acute renal failure Lee,Y.H.;Lee,M.H.;Shim,C.K.
- J. Pharmco. l Exp. Ther. v.279 Enhanced inhibition of microsomal cytochrome P-450 in rat liver during diltiazem biotransformation Murray,M.;Butler,A.M.
- Eur. J. Pharmacol. v.24 Pharmacokinetics of diltiazem in severe renal failure Pozet,N.;Brazier,J.L.;Aissa,A.H.;Khenfer,D.;Faucon,G.;Apoil,E.;Traeger,J.
- Cardiovasc. Drugs Ther. v.4 Renal effects of calcium entry blockers Ruilope,L.M.;Alcazar,J.M.
- Chem. Pharm. Bull. v.19 The whole body autoradiographic studies on the disposition of 14C-labeled new 1,5-benzothiazepine derivative(14C-CRD-401)in mice Sakuma,M.;Yoshikawa,M.;Sato,Y.
- Cardiovasc. Drugs Ther. v.10 Pharmacological aspects of calcium channel blockers Scholz,H.
- J. Cardiovasc. Pharmacol. v.10 Renal actions of calcium antagonists Sterzel,P.B.
- J. Pharmacol. Exp.Ther. v.282 Role of CYP3A4 in human hepatic diltiazem N-deme-thylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolite Sutton,D.;Butler,A.M.;Nadin,L.;Murray,M.I.
- Biopharm. Drug Dispos. v.12 Pharmacokinetics of intravenous diltiazem and five of its metabolites in patients with chronic renal failure and in healthy volunteers Tawashi,M.;Marc Aurele,J.;Bichet,D.;Spenard,J.;Lariviere,L.;Plante,D.;Caille,G.E.
- Biopharm. Drug. Dispos. v.12 Pharmacokinetics of oral diltiazem and five of its metabolites in patients with chronic renal failure Tawashi,M.;Marc Aurele,J.;Bichet,D.;Spenard,J.;Lariviere,L.;Plante,D.;Caille,G.E.
- J. Pharm. Dyn. v.4 A pharmacokinetics analysis program for microcomputer Yamaoka,K.;Tanigawara,Y.;Nakagawa,T.;Uno,T.